DNA VaccinesMark W. Saltzman, Hong Shen, Janet L. Brandsma Springer Science & Business Media, 2008 M02 2 - 384 pages In the early 1990s, almost 200 yr after Edward Jenner demonstrated the effectiveness of the smallpox vaccine, a new paradigm for vaccination emerged. The conventional method of vaccination required delivery of whole pathogens or structural subunits, but in this new approach, DNA or genetic information was administered to elicit an immunological response. Once it was observed that plasmid DNA delivered in vivo led to production of an encoded transgene (1), two ground-breaking studies demonstrated that immunological responses could be generated against antigenic transgenes via plasmid DNA delivered by DNA vaccination (as this approach is called) (2,3). The appe- ance of this new vaccination strategy coincided with advances in molecular biology, which provided new tools to study and manipulate the basic elements of an organism’s genome and also could also be applied to the design and production of DNA vaccines. DNA Vaccines is a major updated and enhancement of the first edition. It reviews state-of-the-art methods in DNA vaccine technology, with chapters describing DNA vaccine design, delivery systems, adjuvants, current appli- tions, methods of production, and quality control. Consistent with the approach of the Methods in Molecular Medicine series, these chapters contain detailed practical procedures on the latest DNA vaccine technology. The enthusiasm for DNA vaccine technology is made clear by the number of research studies published on this topic since the mid-1990s. |
From inside the book
Results 1-5 of 46
Page v
... effectiveness of the smallpox vaccine, a new paradigm for vaccination emerged. The conventional method of vaccination required delivery of whole pathogens or structural subunits, but in this new approach, DNA or genetic information was ...
... effectiveness of the smallpox vaccine, a new paradigm for vaccination emerged. The conventional method of vaccination required delivery of whole pathogens or structural subunits, but in this new approach, DNA or genetic information was ...
Page vi
... effectiveness. For example, a Phase II clinical trial investigating precancerous cervical lesions from HPV retro- spectively reported a statistically significant resolution of lesions in women younger than 25 yr (7). Unfortunately, in ...
... effectiveness. For example, a Phase II clinical trial investigating precancerous cervical lesions from HPV retro- spectively reported a statistically significant resolution of lesions in women younger than 25 yr (7). Unfortunately, in ...
Page vii
... effectiveness of that response in preventing or treating disease. One important clinical application of DNA vaccines may be to complement or augment traditional vaccines. For example, DNA vaccines have been tested in patients who failed ...
... effectiveness of that response in preventing or treating disease. One important clinical application of DNA vaccines may be to complement or augment traditional vaccines. For example, DNA vaccines have been tested in patients who failed ...
Page 4
... effective anti-tumor response could be induced by vaccination to induce anti- body responses to other tumor-associated cell transmembrane proteins. DNA vaccines designed to eliminate an established infection or a tumor aim to produce ...
... effective anti-tumor response could be induced by vaccination to induce anti- body responses to other tumor-associated cell transmembrane proteins. DNA vaccines designed to eliminate an established infection or a tumor aim to produce ...
Page 8
... effective than their VP22-negative counterparts (18). 3.5. Augmentation of the Immunogenicity of the DNA Vaccine Immunogenicity may be augmented by directing the immune response to spe- cific epitopes known to induce protective or ...
... effective than their VP22-negative counterparts (18). 3.5. Augmentation of the Immunogenicity of the DNA Vaccine Immunogenicity may be augmented by directing the immune response to spe- cific epitopes known to induce protective or ...
Contents
11 | |
A Stress ProteinFacilitated Antigen Expression System | 41 |
Weiwen Jiang Charles F Reich and David S Pisetsky | 55 |
Delivery of DNA Vaccines Using Electroporation | 73 |
and Methodology | 83 |
Sylvia van Drunen Littelvan den Hurk Shawn Babiuk | 91 |
for DNA Vaccine Delivery | 107 |
Subcellular Trafficking Pathways by Indirect | 127 |
Sandra Scheiblhofer Richard Weiss Maximilian Gabler | 221 |
Immunological Responses of Neonates and Infants | 239 |
DNA Vaccines for Allergy Treatment | 253 |
Protection From Autoimmunity by DNA Vaccination | 269 |
Immune Mechanisms | 281 |
DNA VACCINE PRODUCTION PURIFICATION AND QUALITY | 293 |
Production of Plasmid DNA in Industrial Quantities According | 339 |
LargeScale Nonchromatographic Purification of Plasmid | 351 |
Adjuvant Properties of CpG Oligonucleotides in Primates | 139 |
Complexes of DNA Vaccines With Cationic Antigenic Peptides | 159 |
PrimeBoost Strategies in DNA Vaccines | 171 |
Modifying Professional AntigenPresenting Cells to Enhance | 199 |
Assuring the Quality Safety and Efficacy of DNA Vaccines | 363 |
Index | 375 |
Other editions - View all
Common terms and phrases
acid activation adjuvants antibody antigen antigen-specific APCs approx assay bacterial DNA Biojector buffer cationic CD8+ T cells cellular centrifuge chromatography clinical trials cloning codon coli concentration conjugation containing cover slips CpG motifs CpG ODN culture cytokine delivery dendritic cells detection diluted DL-DNA DNA vaccines electroporation ELISPOT encoding endotoxin enhance enzyme epitopes ethanol expression filter g/mL gene gun genomic human immune responses immunogenicity Immunol immunostimulatory Incubate induce injection Invitrogen lysate lysis macaques medium Methods and Protocols MHC class mice microspheres Molecular molecules mouse mRNA needle-free neonates Note oligodeoxynucleotides oligonucleotides optimal PBMC pDNA pellet peptide plasmid DNA plate PLGA Prepare priming production protein purification Qiagen receptor recombinant Resuspend room temperature RPMI sample sequence serum solution specific sterile stimulation strategies supernatant syringe T-cell T-cell responses target tion tissue transfected tube tumor vector viral virus vitro vivo Wash µg/mL